Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

The market is likely underpricing how much of this segment is still an adoption story rather than a winner-take-all share war. Oral access lowers the friction for first-time GLP-1 users, which helps the incumbent with the stronger brand and physician familiarity, but the bigger economic effect is that it expands the eligible pool and should support class growth for both names over the next 12-18 months.

The key second-order risk for Novo is that an early script lead can mask a weaker persistence curve once real-world adherence is tested; food/water restrictions and GI tolerability matter more after the first fill than they do in launch-week script counts. If discontinuation rates rise, the oral advantage becomes a short-lived marketing win rather than a durable franchise shift. For Lilly, the real upside is not defending current oral share, but using label expansions in diabetes and sleep apnea to turn its oral asset into a multi-indication platform with broader payer acceptance.

Consensus is probably too focused on near-term prescription share and not focused enough on mix and margin. Oral penetration should be accretive to market size but potentially dilutive to pricing power if payers use it as a step-therapy entry point before pushing patients toward cheaper alternatives or higher-rebate channels. The likely falsifier for a bullish Novo view is a sharp slowdown in refill rates or evidence that the oral cohort is mostly one-and-done convenience seekers rather than durable chronic users.